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Abstract
The human gut microbiota gained tremendous importance 
in the last decade as next-generation technologies of se-
quencing and multiomics analyses linked the role of the mi-
crobial communities to host physiology and pathophysiol-
ogy. A growing number of human pathologies and diseases 
are linked to the gut microbiota. One of the main mecha-
nisms by which the microbiota influences the host is through 
its interactions with the host immune system. These interac-
tions with both innate and adaptive host intestinal and ex-
traintestinal immunity, although usually commensalistic 
even mutualistic with the host, in some cases lead to serious 
health effects. In the case of allogenic hematopoietic stem 
cell transplantation (allo-HSCT), the disruption of the intesti-
nal microbiota diversity is associated with acute graft-ver-
sus-host disease (GvHD). Causing inflammation of the liver, 
skin, lungs, and the intestine, GvHD occurs in 40–50% of pa-
tients undergoing allo-HSCT and results in significant post-
transplantation mortality. In this review, we highlight the im-
pact of the gut microbiota on the host immunity in GvHD 
and the potential of microbiota in alleviation or even preven-
tion of GvHD. © 2018 The Author(s) 
Published by S. Karger AG, Basel
The human body is colonized by a multitude of micro-
organisms, commonly referred to as the microbiota, with 
their associated genomes being referred to as the micro-
biome. Although most of these organisms are bacteria, 
others include viruses, fungi, and archaea. The gastroin-
testinal tract maintains the largest microbial community 
with an estimated 100 trillion bacterial cells from 100–
150 species [1]. The gut microbiota performs diverse 
functions for the host such as the development and matu-
ration of the host immune system, the digestion of food, 
synthesis of essential amino acids, secondary metabolites, 
short-chain fatty acids (SCFAs) and vitamins, the metab-
olism of xenobiotics, modulation of the immune respons-
es, and the resistance to pathogens. In a healthy person, 
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the gut microbiota constitutes a balanced composition of 
different commensals, symbionts and pathobionts (see 
glossary in Table 1) which maintain functional homeo-
stasis essential for human health. Being individual-specif-
ic, the composition of a healthy microbiota may be differ-
ent for people according to their age, geographical loca-
tion and genetics [2]. In addition, the gut microbiota may 
change over time as it is influenced by other external en-
vironmental factors such as major diet changes, antibiot-
ics treatment, and important lifestyle changes. Some-
times, such changes alter microbiota composition with 
either a decrease in symbionts and commensals and/or an 
increase in pathobionts perturbing the symbiotic equilib-
rium. Perturbations in the gut microbiota have been as-
sociated with obesity, type 2 diabetes, metabolic syn-
drome, irritable bowel syndrome, autoimmune diseases, 
and neurodevelopmental disorders [3]. There are bidirec-
tional interactions between the microbiota, immunity, 
and diet (Fig. 1). Changes in the gut microbiota can have 
profound effects on the host immune system. This could 
be seriously detrimental to the success of therapy for a 
variety of malignant and benign hematological diseases 
for which allogenic stem cell transplantation is the only 
curative treatment.
Table 1. Glossary
ARG Antibiotic resistance gene, gene conferring resistance to antibiotics; the resistance 
can be intrinsic (naturally occurring, independent of previous exposure to 
antibiotics) or acquired (via horizontal gene transfer or by mutation)
Commensal A nonharmful coexistence of an organism in a host
Bacteriotherapy It is the administration of live bacteria (probiotics) or their products (bacteriocins) 
to restore health or cure disease
FMT Fecal microbiota transplant; a process of transferring a fecal suspension containing 
the fecal microbiota, from a healthy individual into a recipient (patient)
Gut microbiome It refers to the group of microbial genomes of the microbial communities of the 
gastrointestinal tract (also called the gut)
Gut microbiota It is the ensemble of all microorganisms such as bacteria, archaea, fungi, and viruses 
inhabiting the gut
GvHD Graft-versus-host disease; a complication after allogenic stem cell transplantation in 
which T cells from the donor (graft) immunologically attack the host’s tissue
Metagenomics It is the study of the collective genetic material in a sample usually directly taken 
from an environment; it provides information on the taxonomic composition and 
functional potential of a microbial community
Metatranscriptomics It is the study of the sets of transcripts of microorganisms from an environmental 
sample; it gives information on the functional profile of a microbial community 
within the given sample
Mutualistic It is type of symbiotic relationship between two organisms in which each symbiont 
benefits from the activity of the other
Pathobiont These are potentially pathological organisms which can cause diseases in 
predisposed hosts
Prebiotics Nondigestible fiber compounds that are substrates for the microorganisms usually 
bacteria colonizing the gut having stimulatory effect on these bacteria
Probiotics Live microorganisms which can confer health benefits to a host
SCFA Short-chain fatty acids; produced by bacterial anaerobic fermentation in the gut and 
are main energy providers to colonocytes
Symbiont An organism living in symbiosis with a dissimilar host in a mutualistic or parasitic 
(with potential to cause pathology) relationship
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Interaction between the Gut Microbiota and the 
Host Immune System
Physical barriers in the gut such as the mucus layer 
produced by goblet cells, and the tight junctions regulate 
the relationship between the microbiota and the host [4]. 
Intestinal epithelial cells, dendritic cells, and macro-
phages express pattern recognition receptors such as 
Toll-like receptors and nucleotide-binding oligomeriza-
tion domain-like receptors which recognize microbe-as-
sociated molecular patterns. Activation of these receptors 
triggers a range of effects from a proinflammatory cyto-
kine response to the presentation of antigens to regula-
tory T cells (Tregs). Activation of Tregs conveys tolerance 
towards commensal bacteria from the initial colonization 
of the gut during early life [4]. Some gut bacteria produce 
SCFAs such as butyrate, propionate, and acetate. SCFAs 
play roles in both innate and adaptive immunity. Among 
other activities, SCFAs have histone deacetylase inhibi-
tory activity through which they exert anti-inflammatory 
effects on the macrophages and the dendritic cells [5]. 
Butyrate is one of the most important energy sources for 
enterocytes and exerts anti-inflammatory activity by in-
hibiting NF-κB signaling and increasing IL-10 expression 
[6]. Moreover, it maintains the epithelial integrity by up-
regulation of the expression of tight junction proteins and 
the production of mucin by the goblet cells.
Whilst most bacteria occupy the gut lumen, segment-
ed filamentous bacteria can penetrate the mucus layer 
and interact closely with the epithelial cells, inducing sig-
nalling events that lead to the differentiation of T helper 
(TH) 17 cells [7]. These are CD4+ effector T cells which 
are specialized in responses to extracellular bacteria and 
fungi by secretion of cytokines such as IL-17A, IL-17F, 
IL-21, and IL-22 [7]. Activation of TH17 cells is the host’s 
protection against gastrointestinal pathogens. It is also as-
sociated with proinflammatory systemic effects [4]. The 
cytokines produced by TH17 cells induce secretion of an-
timicrobial peptides (AMPs) such as the α-defensins and 
RegIIIγ by the Paneth cells [4]. While strengthening the 
tight junctions, TH17 cells also promote the production 
of immunoglobulin A (IgA). T cell-dependent IgA secre-
tion plays an important role in adaptive immunity. IgA 
maintains microbiota diversity and its compartmental-
IgA
, AM
P, R
egI
IIγ,
NO
, re
act
ive
 O2
,
pha
goc
yte
s
SCF
As
Phe
nol
 me
tab
olit
es
TLR
/NO
D l
iga
nds
Immunity
Microbiota
Diet
Nutrient absorption
Vitamin A and D,
AhR ligands, folate, iron
Fermentation,
nutrient absorptionFiber, fat, sugar,
iron, vitamin A
Fig. 1. Bidirectional interactions between microbiota, immunity, 
and diet (adapted from Belkaid and Hand [4]). Dietary compo-
nents such fiber, fat, sugars, and trace nutrients modulate micro-
biota composition and metabolic capacity. Microbiota help in di-
gestion and nutrient uptake. Dietary nutrients and metabolites 
(such as AhR ligands) produced by microbiota modulate the im-
munity. The host immune system can affect the nutrient uptake. 
The immune system regulates microbiota by various mechanisms 
such as AMP, IgA, reactive oxygen species, and phagocytosis. The 
microbiota in turn produces metabolites that modulate the func-
tioning of the immune system.
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ization. Loss of TH17 cells and their protective functions 
are associated with bacterial translocation [8]. B cells also 
secrete IgA that regulates interactions of the host with the 
commensals and prevent their adhesion to the epithelial 
surfaces [8]. In addition to protecting the intestinal epi-
thelium from pathogenic bacteria, viruses and toxins, IgA 
can also downregulate proinflammatory responses and 
the expansion of Tregs cells.
Patients with hematological diseases requiring stem 
cell transplantation undergo extensive preconditioning 
chemotherapy as well as supportive measures such as an-
tibiotic or antifungal treatments. These interventions re-
sult in the disruption of the gut microbiota and its equi-
librium. Although antibiotic treatment in stem cell trans-
plant patients is meant to avoid bacterial infections and is 
essential in many patients, recent studies link these to a 
higher risk of developing bacterial infections from oppor-
tune pathogens and subsequently graft-versus-host dis-
ease (GvHD). A significant number of patients receiving 
allogenic stem cell transplantation develop GvHD, which 
causes up to 30% mortality in these patients [9].
Allogenic Hematopoietic Stem Cell Transplantation 
and GvHD
Intensive treatment of hematological malignancies 
with radiation and chemotherapy targets the malignant 
cell clones but also results in severe damage to the gut 
epithelia. Compromised barrier allows microorganisms 
or bacterial products to enter the blood circulation [10]. 
Consequently, the immune response in the form of in-
flammatory cytokines leads to inflammation, blood-
stream infections (BSI), i.e. bacteremia and fungemia, 
GvHD, and sepsis [10]. BSI are predominantly caused by 
Pseudomonas aeruginosa, Escherichia coli, and Candida 
albicans [10]. To prevent BSI in patients receiving al- 
logenic hematopoietic stem cell transplantation (allo-
HSCT), very often prophylactic antibiotics are used. 
There are conflicting reports about the use of antibiotics, 
with some studies reporting a remarkable decrease in the 
GvHD mortality and others associating it to increased 
morbidity and mortality. This is partly due to the indis-
criminate use of antibiotics without considerations of pa-
tient-specific microbiota composition. Moreover, wide-
spread and standard use of broad-spectrum antibiotics 
has resulted in an increasing number of antibiotic-resis-
tant bacteria [11]. Both mortality as well as incidence of 
acute GvHD were higher in allo-HSCT recipients who 
were colonized by antibiotic-resistant bacteria [11, 12]. 
An integrated meta-omics analysis determined a higher 
number and expression of antibiotic-resistant genes 
(ARGs) in the gut microbiome of a patient after allo-
HSCT who died due to GvHD [13]. Another retrospec-
tive study indicated that the treatment of neutropenic fe-
ver with antibiotics such as imipenem-cilastatin and 
piperacillin-tazobactam was linked to increased GvHD-
related mortality within 5 years [14]. Other recent studies 
also link prophylactic use of antibiotics to higher trans-
plant-related mortality [15, 16].
Studies focusing on the microbiota composition in pa-
tients before and after allo-HSCT, report a drastic loss of 
bacterial diversity after the treatment. This loss of diver-
sity was more pronounced in patients who developed gut 
GvHD [17]. Loss of microbiota diversity is linked to an 
increased risk of infections and GvHD [18]. The decrease 
in diversity following allo-HSCT is often accompanied by 
the expansion of a single taxon. In most cases, at the onset 
of GvHD, an increase in the abundance of the members 
of the genus Enterococcus has been observed [17, 19]. This 
is frequently followed by BSI with vancomycin-resistant 
Enterococci and a decrease in the abundance of members 
of the order Clostridiales including Faecalibacterium spp. 
and Ruminococcus spp. [19, 20]. The majority of the 
members of the order Clostridiales are Gram-positive ob-
ligate anaerobes and are the most abundant commensal 
bacteria of the gut. Many of these are known butyrate pro-
ducers [21]. Butyrate is involved in increased histone 
acetylation resulting in increased expression of antiapop-
totic proteins such as JAM and occludin which are in-
volved in barrier integrity [22]. Administration of 17 
strains of butyrate-producing clostridia species improved 
gut epithelial integrity, reduced GvHD specific damage, 
and improved survival after allo-HSCT in a murine mod-
el [22, 23]. Butyrate produced by these commensal bacte-
ria induces Treg cell expansion and differentiation [23, 
24]. Recently, higher abundance of another Clostridiales 
member, the genus Blautia, was linked to reduced GvHD-
related mortality [25].
In addition to producing immunomodulatory metabo-
lites, the gut microbiota confers colonization resistance 
against pathogens [26] by preventing these from colonizing 
the gut. The commensals induce the production of AMPs 
by the Paneth cells. These AMPs keep the pathogens at bay. 
Severe gut GvHD correlates with a decrease in Paneth cells 
in biopsies [27]. The leaky epithelial barrier allows translo-
cation of pathogens and/or antigens thereof into the sys-
temic circulation causing BSI. Infiltration of these patho-
genic antigens into other organs elicits local immune re-
sponses leading to organ damage as seen in GvHD.
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Summarizing, the host defense system comprises cel-
lular immunity, intact intestinal barrier, and balanced 
microbiota. In patients undergoing allo-HSCT, very of-
ten these three defense mechanisms are compromised 
(Fig. 2). The therapy requires immunosuppression and 
cytotoxic chemotherapy resulting in severe neutropenia 
and massive intestinal barrier damage (mucositis). In ad-
dition, prophylactic antibiotics used to decontaminate 
the gut result in significant imbalance of the microbial 
community of the gut possibly favoring colonization by 
pathogens especially antibiotic-resistant strains. Ulti-
mately, the microbial dissemination from the gut leads to 
sepsis and GvHD.
Potential of Microbiota as Therapeutic Intervention
Increasing understanding of the implication of the 
gut microbiota in GvHD is opening an opportunity to-
wards evidence-based therapy for patients undergoing 
allo-HSCT. The modulation of gut microbiota accord-
ing to the specific needs of patients will be an important 
part of the therapeutic strategy for allo-HSCT patients 
in the future. Moreover, dynamic monitoring of the mi-
crobiota may provide biomarker signatures for optimal 
therapeutic outcome and follow-up in the allo-HSCT 
patients.
Modulators of the Gut Microbiota
Recent research indicates that the modulation of gut 
microbiota may represent a potential therapeutic inter-
vention to alleviate and even prevent GvHD in allo-HSCT 
patients. The gut microbiota can be temporarily manipu-
lated by the choice of the antibiotics and the use of probi-
otics/prebiotics to repopulate the gut with commensals. 
The risk of invasive BSI is directly proportional to the 
microbial burden in the gut. It was shown that a 2-log re-
duction of bacterial and fungal colonization of the gut is 
enough to significantly reduce pathogenic microbial 
translocation from the gut. As such, antibiotic-indepen-
dent approaches also hold promise as therapeutic op-
tions. Probiotics, fecal microbiota transplant (FMT), and 
prebiotics are all viable options. Other methods to modu-
late the gut immunity are strategies such as genetically 
engineered bacteria, CRISPR-Cas9 phagemids, bacterial 
ligands, and pathogen-specific antibodies.
Antibiotic Therapy
The use of broad-spectrum antibiotics clindamycin, 
piperacillin-tazobactam, and imipenem-cilastatin are 
linked to GvHD in patients [15]. In allo-HSCT patients, 
common pathogens are Gram-negative bacteria (En-
terobacteriaceae) and Gram-positive bacteria such as co-
agulase-negative Staphylococci, Streptococcus viridans, 
Healthy individual Allo-HSCT patient
Gut microbiota
High diversity
Colonization resistance
Intestinal barrier function
Synthesis of vitamins/SCFAs
Immunomodulatory functions
Loss of diversity
GvHD (GI tract, skin, liver)
Loss of colonization resistance
(extension of pathogens)
Dysfunctional synthesis of vitamins/
SCFAs
Intestinal barrier integrity compromised
(microbial translocation; BSI; sepsis)
Inflammation (endotoxins, cytokines,
activation of antigen-presenting cells)
Conditioning
treatment
and supporting
therapy
with antibiotic or
anti-fungal
agents
Fig. 2. Gut microbiota in a healthy individual and in an allo-HSCT patient. Cancer conditioning treatment and 
supporting therapy with antibiotics or antifungal agents disrupt the microbiota and its functions (left panel) re-
sulting in a range of side effects (right panel) that lead to GvHD causing significant mortality in allo-HSCT pa-
tients.
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Enterococcus, and Candida species. Identification and 
monitoring of these common known pathogens in pa-
tients could help in the choice of the antibiotics. Narrow-
spectrum antibiotics, which target specific pathogens, 
while avoiding emergence of antibiotic resistant strains 
may prevent the complications caused by empiric anti-
biotics. About one-third of the pretransplant patients 
develop infection from Clostridium difficile, an oppor-
tune pathogen which colonizes the gut when the com-
mensals especially the Clostridiales (anti-inflammatory 
clostridia or AIC) are depleted by broad-spectrum anti-
biotics [28]. The AIC reduction is also linked to expan-
sion of Enterococcus spp. in patients who develop GvHD. 
As such, real-time monitoring of AIC with quantitative 
polymerase chain reaction (qPCR) or metabolomics [29] 
could be used to guide therapy in two ways; first in con-
firming that the antibiotics are not depleting the AIC 
below a critical range and secondly by providing in time 
decisions towards strategies to repopulate (probiotics) 
and/or sustain (antibiotics termination or prebiotics) 
the microbiota. Other gut-protective measures such as 
exogenous SCFAs or inducers of gut AMP can also be 
considered.
Antibiotic-independent approaches include the use of 
bacteriocins and bacteriophages. Bacteriocins are bacte-
rial AMPs, and phages are viruses that infect and kill bac-
teria. These are natural components of the microbial 
communities and support competition, survival, and mi-
crobial diversity. Since these are very specific precision 
killers, they may be used to control specific pathogenic 
colonization of the gut. Although many studies with bac-
teriocins and bacteriophages are available and are ongo-
ing for inflammatory bowel disease and Crohn’s disease 
[30], to our knowledge there is limited or no information 
on their use in allo-HSCT patients.
Probiotics and Prebiotics
 Specific strains of bacteria confer resistance to patho-
gens by either occupation of intestinal niches, competi-
tion for nutrients or even by induction of host immunity 
towards these pathogens. One such example is coloniza-
tion with Barnesiella which was shown to protect against 
intestinal domination with vancomycin-resistant Entero-
cocci and subsequent BSI [31].
Gut microbiota is directly influenced by diet. Several 
studies have demonstrated a protective effect of enteral 
feeding in GvHD [32]. On the other hand, total paren-
teral feeding enhances proinflammatory cytokines [33] 
and most likely aggravates the immune responses in al-
lo-HSCT patients. The diet effects are due to the prebi-
otics (indigestible carbohydrates). Upon fermentation 
of these prebiotics by the microbiota, the SCFAs are pro-
duced. The SCFAs aliment and promote the intestinal 
enterocytes by providing energy and exerting an anti-
apoptotic effect on these. Exogenous butyrate was shown 
to restore barrier integrity, protect the enterocytes and 
alleviate GvHD. The SCFAs play a central role in anti-
inflammatory pathways through the induction of Tregs 
which produce anti-inflammatory cytokines. This shift 
in balance towards anti-inflammatory cytokines in turn 
may directly modulate the incidence and the severity of 
GvHD.
Other bacterial metabolites that maintain the epithe-
lial barrier integrity and functions are bile acids, poly-
amines, and aryl hydrocarbon receptor (AhR) ligands 
[34]. Bile acids have enteroprotective effects via the 
Farnesoid X receptor in the intestinal epithelium [34]. 
Polyamines such as spermine and spermidine have been 
shown to improve intestinal epithelial integrity by mod-
ulating E-cadherin expression via c-Myc. Spermine has 
been shown to modulate adaptive immunity by regulat-
ing macrophage activation and inhibiting proinflamma-
tory cytokines. AhR ligands play an important role in the 
proper function and regeneration of the epithelial bar-
rier in addition to secretion of AMPs by the Paneth cells. 
Lactobacilli produce indole-3-aldehyde from trypto-
phan which is a known AhR ligand. Other dietary com-
ponents, especially those derived from the family Bras-
sicaceae, are metabolized by the gut microbiota to in-
dole-containing moieties and have protective effects on 
the intestinal mucosa. A study demonstrated reduced 
Enterococcus translocation and reduced mortality in 
HSCT patients who were administered fiber, glutamine, 
and oligosaccharides [35]. A clinical study investigating 
the effect of resistant starch as prebiotic to induce buty-
rate production by the microbiota for the prevention 
of acute GvHD is ongoing (www.clinicaltrials.gov: 
NCT02763033). Another clinical study focusing on the 
effects of probiotics in both acute and chronic GvHD 
is underway (www.clinicaltrials.gov: NCT02805075, 
NCT02144701).
Fecal Microbiota Transplant
FMT is probably the most effective probiotic to re-
store the gut microbial diversity. FMT was used to suc-
cessfully treat recurrent C. difficile infections (CDI) [36]. 
Some studies with small numbers of patients have dem-
onstrated the beneficial effects of FMT, with 3 out 4 pa-
tients achieving complete remission of GvHD [37]. In 
the case of allogenic HSCT patients, repeated FMT in 
Gut Microbiota and Hematopoietic Cell 
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patients who developed GvHD resulted in alleviating the 
symptoms of the disease [38]. Yet another recent study 
demonstrated that FMT could reduce intestinal coloni-
zation by antibiotic-resistant strains in patients with he-
matological malignancies [39]. Patients with a history of 
colonization with antibiotic-resistant strains such as C. 
difficile may be prioritized to receive FMT before they 
undergo HSCT. In this direction, a clinical study is eval-
uating the role of autologous FMT in allo-HSCT patients 
to prevent posttransplant CDI (www.clinicaltrials.gov: 
NCT02269150). Another clinical study (www.clinical 
trials.gov: NCT02733744) is focusing on the benefits of 
FMT after allo-HSCT on the incidence of acute GvHD as 
well as 2-year survival in these patients.
Personalized Medicine
Some patients experience expansion of pathogenic 
strains and develop invasive infections and GvHD where-
as others do not. This is partly because the gut microbio-
ta and its interaction with the host is individual specific. 
As such, the microbial profiling provides an opportunity 
for personalized medicine (Fig.  3). To understand the 
causal links between microbiota and cytokines involved 
in GvHD, a study (www.clinicaltrials.gov: NCT02398708) 
will compare the fecal microbiota of patients who develop 
chronic GvDH with those who do not.
Microbial Profiling
Frequently used techniques of microbial profiling are 
16S rRNA sequencing and the unbiased high-resolution 
method of metagenomics shotgun sequencing (MSS). On 
the other hand, in situ hybridization and PCR have been 
used to identify and quantify bacteria.
The gene encoding the 16S ribosomal RNA subunit 
contains regions that are highly conserved between dif-
ferent bacterial species and nine hypervariable regions 
that are unique for specific bacterial species. Bacterial 
communities can be identified by sequencing these vari-
able regions. This method allows comparison of identi-
fied bacterial taxa over time. It does not however provide 
the definitive identification of the bacterial strain. Se-
quences are clustered into phylotypes called operational 
taxonomic units based on their similarity. A reference da-
tabase is needed for taxonomic identification. Open-
source software such as Mothur and QIIME are used to 
analyze 16S rRNA sequencing data.
MSS provides an unbiased sequencing of all the ge-
netic material present in a sample. The extracted gDNA 
undergoes massively parallel sequencing to provide a 
wide coverage of the microbial communities. MSS can 
detect very-low-abundance microorganisms due to high 
sequence coverage. The MSS data are used for taxonomic 
identification as well as functional analysis. Taxonomic 
classification is carried out using unique clade-specific 
marker genes or lowest common ancestor methods. At 
Gut microbial profiling
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Fig. 3. Gut microbiota profiling and per-
sonalized medicine. Changes in individual 
microbiota such as loss of diversity and an-
ti-inflammatory Clostridiales or expansion 
of pathogen(s) could be investigated using 
qPCR, 16S rRNA, and/or metagenomics 
shotgun sequencing. The microbiota pro-
files will facilitate risk identification and 
stratification of patients, for example pa-
tients at risk for CDI infections. In this way, 
various intervention strategies could be 
used and followed up for effects. These in-
dividual specific therapeutic interventions 
could alleviate GvHD improving survival 
by decreasing pathogen burden and micro-
bial dissemination. GIT, gastrointestinal 
tract.
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the same time, functionality could be assessed from the 
pathway mapping of the sequenced genes using, for ex-
ample, Kyoto Encyclopedia of Genes or Genomes Orthol-
ogy Database. MSS can also provide comprehensive in-
formation on the ARGs giving a snapshot of the resistome.
Microbial metagenomics sequencing and metabolo-
mics profiling are important tools in understanding the 
correlation between taxon level changes and metabolic 
functions in the host. These techniques are expected to 
provide causal relationships and help in establishing 
functional correlates. For example, CDI is frequent in al-
lo-HSCT patients, and some patients have predetermined 
higher risk for CDI before conditioning therapy. Stratify-
ing this population of patients will help improve therapy 
success in these patients.
Prognosis/Therapy Follow-Up
Since the microbiota regulates host immunity and 
plays a potential role in the onset and severity of GvHD, 
the microbiota signatures could become very important 
therapy follow-up criteria. Increased gut microbial bur-
den, e.g. increased abundance of E. coli is indicative of 
increased risk of bacteremia. Therefore, monitoring of 
gut Enterobacteriaceae strains (such as E. coli, Klebsiella 
spp. and Enterobacter spp.) in allo-HSCT patients could 
identify patients at risk and can be greatly helpful to min-
imize Enterobacteriaceae bacteremia. The interactions of 
the microbiota with host immunity can have long-term 
effects. These interactions could thus be used to identify 
patients at risk for disease relapse. A retrospective study 
on a large cohort linked the presence of SCFA-producing 
Gram-positive Eubacterium limosum with reduced risk of 
disease relapse [40].
Microbiota as Noninvasive Biomarker for GvHD
The main target organs of GvHD are skin, gastrointes-
tinal tract, and the liver. The severity is determined based 
on the degree of involvement of the three principle target 
organs. The diagnosis is differential based on biopsy and 
histological examination. The therapy for GvHD is rarely 
started before a definitive diagnosis is made. Changes in 
the microbiota may provide noninvasive biomarker signa-
tures to guide the therapy. For example, a qPCR for AIC 
species could be used to monitor the AIC concentration 
frequently. A critical depletion of the AIC could be indica-
tive of high risk for GvHD, and appropriate therapy could 
be initiated. In addition, the same technique could allow 
monitoring the success of the therapy. The application of 
bacterial qPCR in routine clinical analysis for allo-HSCT 
patients warrants large studies including validation.
Urine metabolomics is another noninvasive way to 
identify bacterial metabolite biomarkers. Recently, in-
doxyl sulfate was shown to correlate with intestinal AIC 
abundance [30]. Low concentration of this metabolite 
was associated with poor outcome in GvHD patients.
Challenges in Widespread Use of Microbiota 
Modulation in HSCT Patients
Many of the challenges to the application of microbio-
ta in the diagnosis, prognosis, and therapy of GvHD are of 
technical nature. Although culture-independent tech-
niques of microbial profiling such as the 16S rRNA se-
quencing and the MSS sequencing have significantly ad-
vanced the microbiome research, they remain too costly, 
time consuming, and complex to be applied on a routine 
clinical basis. Another limitation of these techniques is 
that they give the relative abundance but not the absolute 
levels of the microbial communities. As such, these meth-
ods do not provide quantitative assessment of the total 
microbiota levels. Both the 16S rRNA and MSS techniques 
require refined computational methods and bioinformat-
ics platforms. Validated databases are not only needed to 
draw taxonomic identification as in the case of 16S rRNA 
sequencing but also to find functional attributes by look-
ing at the pathways and the involved genes in the case of 
MSS. As more scientists use these techniques, guidelines 
for the standardization and harmonization of sample pro-
cessing and data acquisition will be required. This will be 
challenging as the microbiota is only partially known and 
more and more knowledge will be added in the coming 
years. Moreover, this means that there is a constant need 
to update the databases and the functional information. 
Bioinformatics tools will undergo continuous upgrading 
and development as huge datasets will be analyzed.
Species-specific qPCR could be a rapid method to ob-
tain dynamic information on specific microbial commu-
nities. The technique is inexpensive and is clinically used 
in the screening of pathogens such as cytomegalovirus. In 
addition, qPCR has validated use in 16S rRNA sequencing 
for the quantification of bacterial groups and species. 
However, qPCR is limited by the fact that it will not pro-
vide an overall snapshot of the whole gut microbiota. The 
challenge in the routine clinical use of this method is to 
define specific and validated group(s) of bacteria that need 
to be continuously monitored in allo-HSCT patients. As 
more and more studies are published, it is expected that 
the scientific community could agree upon such a panel of 
specific microorganisms in the near future.
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It is imperative to understand how the taxa level chang-
es modulate the host homeostasis by influencing the met-
abolic functions. Including information from other omics 
levels especially from the metabolomics, may confirm the 
actual functional activity [41]. At the same time, although 
increasing information is becoming available on the bac-
teria, the involvement and impact of mycobiome and the 
virome in GvHD is poorly understood.
Currently, definite diagnosis of GvHD is difficult in 
the absence of noninvasive biomarkers. Real-time gut mi-
crobiota monitoring using qPCR could provide critical 
thresholds for specific microorganism that maintain epi-
thelial barrier integrity and function. However, this meth-
od suffers from lack of clinical data and validated clinical 
efficacy.
Microbial metabolites could provide an early and pre-
cise indication of the gut microbiota health. Nevertheless, 
further investigations on the role of microbial metabolites 
in GvHD are required. Some examples include the IL-22 
production in response to AhR ligands and Tregs differen-
tiation, both of which have effects on the adaptive im-
mune reactions.
FMT from healthy donors can restore microbiota di-
versity and function. The clinical efficacy of FMT in CDI 
infections is established. FMT has also been used to de-
colonize antibiotic-resistant strains. Although nowadays, 
several studies on the feasibility of FMT are planned while 
some are ongoing, there are concerns that FMT in immu-
nosuppressed patients may provoke further infections. 
Recent work has demonstrated the use of encapsulated 
freeze-dried microorganisms may circumvent this risk 
[42]. Another limitation to the use of FMT is that donor 
and fecal screening is time consuming and may not ac-
curately reflect the microbiota, for example the microor-
ganisms living in the mucous layer may be underrepre-
sented. Alternatively, bacteriotherapy using a defined 
mixture of fecal bacteria could be a solution. Several clin-
ical studies on the investigation of FMT in the prevention 
and/or alleviation of GvHD are ongoing. These studies 
are expected to show the utility and efficacy of FMT as 
therapeutic strategy in allo-HSCT patients.
Perspectives for Therapeutic Strategies Involving 
the Gut Microbiota
The gut microbiota is associated with human health 
and disease. Current technology has facilitated the iden-
tification of the role of gut microbiota in disease process-
es and even established causality in some cases. Monitor-
ing of changes in the gut microbiota could serve as non-
invasive biomarker for GvHD. Profiling tools such as 16S 
rRNA, metagenomic shotgun sequencing (MSS) or 
qPCR provide valuable information on the relative abun-
dance and dynamics of the microbiota. In a clinical set-
ting, qPCR may be applied for real-time monitoring of 
specific microbial strains before, during, and after allo-
HSCT, especially in high-risk patients.
Recent studies support the use of specific and prefer-
ably narrow spectrum antibiotics instead of broad-spec-
trum antibiotics which cause more collateral damage to 
intestinal mucosa and promote emergence of antibiotic-
resistant microbial strains. The mechanistic understand-
ing is also promoting new therapy options for such pa-
tients. One example of such targeted therapy is to conju-
gate a pathogen-specific antibody to an antibiotic [43]. 
Specific pathogens could also be targeted by using CRIS-
PR-Cas9 phagemids [44]. On the colonization resistance 
front, genetically engineered bacteria may be used to 
compete with the pathogens [45]. Inducers of gut AMPs 
and of Toll-like receptors such as LPS [46] or pharmaco-
logical compounds [31, 47] could help reduce pathogen-
ic microbial colonization of the gut and subsequently re-
duce the risk of GvHD.
High-throughput culture techniques, the so called 
culturomics, was applied to determine global microbial 
composition using MALDI-TOF mass spectrometry and 
identified more than 32,000 colonies in human stools 
[48]. This technique nevertheless misses the “nonculti-
vable” microorganisms. Moreover, although a variety of 
culture conditions and microbial compositions can be 
tested, the interactions of the microbial communities 
with the human gut are not possible. Alternatively, a con-
trolled microfluidics-based co-culture system such as 
HuMiX [49] allows growth of bacteria, intestinal epithe-
lial cells, and human immune cells in different chambers 
separated by membranes. Other in vitro systems such as 
the gut-on-the-chip with stem cell-derived organoids 
supporting co-cultures with the microbiome could fa-
cilitate the study of the interactions of the microbial cul-
tures with human gut cells [50]. Another area of major 
focus will be in situ noninvasive sampling from different 
parts of the gut to extend the current knowledge on the 
compartmentalization of the microbiota. A device allow-
ing the isolation and identification of uncultivable mi-
croorganisms is the iChip, and its derivative iTip could 
provide further coverage of the human gut microbiota 
[50].
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Conclusion
As more and more mechanistic insights are becoming 
available, gut microbiota will have a central role in the 
diagnostic and therapeutic strategies for patients under-
going allo-HSCT as well as in the alleviation or even pre-
vention of GvHD. In the future, targeted manipulation of 
the gut immune system would be most likely applied as 
standard care for allo-HSCT patients to improve treat-
ment success and to avoid complications such as the 
GvHD.
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